Uremic toxins: new aspects.
Hörl Wh
Abstract
Hörl Wh
Abstract
Clinical signs and symptoms of end-stage renal failure patients are at least in part related to the accumulation of uremic retention solutes and uremic toxins. This article describes abnormalities caused by asymmetric dimethylarginine, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products, homocysteine as well as low and high molecular weight inhibitors of polymorphonuclear leukocytes. Mechanisms for the accumulation of uremic retention solutes and uremic toxins include decrease of renal function, oxidative stress, microinflammation and/or uremia per se resulting in protein modifications with new biological functions.
OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Clinical signs and symptoms of end-stage renal failure patients are at least in part related to the accumulation of uremic retention solutes and uremic toxins. This article describes abnormalities caused by asymmetric dimethylarginine, advanced glycation end products, advanced lipoxidation end products, advanced oxidation protein products, homocysteine as well as low and high molecular weight inhibitors of polymorphonuclear leukocytes. Mechanisms for the accumulation of uremic retention solutes and uremic toxins include decrease of renal function, oxidative stress, microinflammation and/or uremia per se resulting in protein modifications with new biological functions.
Key concepts: Uremia, Uremic toxins, Glycation, Medicine, Oxidative stress, Homocysteine, Asymmetric dimethylarginine, End stage renal failure